Botox 200 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FBQAA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,772
Award facts
- Contract value 100% obligated
- $20,772.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $20,772 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the delivery of Botox 200 unit vials. The award, issued on January 15, 2026, represents a firm fixed-price delivery order with an ultimate completion date of February 6, 2026, and was not issued under a set-aside designation. This delivery order was executed under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion federal acquisition strategy designed to establish regional prime vendor contractors for pharmaceutical supply to the Department of Defense.
DMS Pharmaceutical Group, headquartered in Park Ridge, Illinois, serves as a critical supplier within the federal pharmaceutical supply chain and has demonstrated substantial contracting activity with the DLA's Medical Supply Chain division. The company's product portfolio spans a comprehensive range of pharmaceuticals including specialty biologics, oncology treatments, vaccines, and medical consumables to support military healthcare facilities worldwide. The PPV-G GEN V parent contract, designated SPE2DR and awarded in November 2025, provides a $499.999 billion ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group to fulfill diverse and specialized pharmaceutical requirements across the Department of Defense's global healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FBQAA?
SPE2DR26FBQAA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FBQAA worth?
The government has obligated $20,772 on SPE2DR26FBQAA.
Is contract SPE2DR26FBQAA an order under another contract?
Yes. SPE2DR26FBQAA is a delivery order under SPE2DR25D9304, an indefinite delivery contract.
Was contract SPE2DR26FBQAA competed?
The extent of competition for SPE2DR26FBQAA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award